Cancer News: Lung
Lung cancers detected by low-dose Computed Tomography (LDCT) were over-diagnosed by 18%, according to a recent study.
For non-small cell lung cancer (NSCLC) at advanced stage, treatments with pemetrexed- and paclitaxel-based chemotherapy, have similar effectiveness but different toxicity.
Statistics covering the period 1975-2010 showed death rates for lung cancer, which accounts for more than 1 in 4 cancer deaths, dropping at a faster pace than in previous years. This is likely the result of decreased cigarette smoking over many years, and is now being reflected in mortality trends.
Patients with isolated chest wall recurrence of malignant pleural mesothelioma (MPM) have improved outcomes with salvage chest wall resection, research indicates.
A study shows that specific gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers.
Don't dogmatically reject e-cigarettes for fear of "renormalization" of cigarettes, one group of public health experts argued.
The recommendation includes annual low-dose Computed Tomography (CT) lung cancer screening for high-risk individuals.
Lung cancer researchers are working on an alternative therapy to boost patients' immune system.
Experts are developing tools to simplify lung cancer prevention and screening recommendations.
Targeted non-small cell lung cancer (NSCLC) therapies with the mutated protein KRas has been shown to be the most effective treatment strategy.
Non Small Cell Lung Cancer (NSCLC) treatment outcomes may be substantially improved through a new type of immunotherapy.
Cancerous behavior in high-risk lung cells was increased when exposed to electronic cigarette vapor in a lab setting.
Lung and bladder cancer biomarker analysis have similar genetic abnormalities. This latest research may have diagnostic, prognostic and treatment implications.
An alarming finding indicates that antioxidants may speed up lung cancer’s progression, instead of halting it (as shown previously). Antioxidants are chemicals present in some pharmaceuticals, foods and nutritional supplements.
The non-small cell lung cancer trial compared ramucirumab (designed to treat multiple tumors) combined with docetaxel, with a placebo combined with docetaxel.
A new protein has been identified as playing a key role in cancer and inflammation in lung tissue. This may help the development of new drugs for the disease.
An investigational cancer vaccine (tecemotide) combined with cisplatin chemotherapy in a trial delivered promising results for stage 3 lung cancer.
Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, in a late-stage trial.
Ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, in tumors resistant to crizotinib & in those never treated with it.
30% of surgeries for non-small cell lung cancer were deemed unnecessary, while positron emission tomography (PET) can reduce unnecessary surgeries by 50%.
Emerging lung cancer treatments will be based on drugs that can use the body's immune system to fight the disease, and prevent tumor cells from affecting it.
A majority of patients given a investigational drug against non-small cell lung cancer actually responded to the treatment, according to clinical trial details.
The risk of developing a primary lung tumor for women who had radiotherapy for breast cancer increases with the radiation amount, according to researchers.
Among patients with advanced non-small cell lung cancer without a certain gene mutation, conventional chemotherapy resulted in longer progression-free survival.
The US FDA has granted accelerated approval for ceritinib (trade name: Zykadia) for treatment of a less common subtype of non-small cell lung cancer (NSCLC).
Retreating lung tumors with radiation is an old idea that has been reintroduced, based on the technological advances in radiation oncology over the last decade.
Targeted therapy for patients with lung adenocarcinoma can help transform treatment for the disease, as many patients have specific genetic characteristics.
In a study, ceritinib shrank tumors in patients with ALK+ non-small cell lung cancer, regardless of prior treatment, in general.
Physical inactivity has been blamed for diseases like diabetes, obesity and cardiovascular disease. Now it is also linked to the risk of certain cancers.
A new device may accurately detect lung cancer and its stage, just by breathing into it, since it can detect specific characteristics of breath compounds.